| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 08/31/2006 | WO2006089493A1 Multilayer tablet comprising separating layers |
| 08/31/2006 | WO2006089317A1 Pharmaceutical dosage form effective at microcirculatory level containing at least one flavonoid |
| 08/31/2006 | WO2006072685A3 Method for preparing a solid pharmaceutical composition with prolonged and controlled release by high pressure treatment |
| 08/31/2006 | WO2006070288A3 Aerosol generator |
| 08/31/2006 | WO2006063411A3 Transfer of molecules |
| 08/31/2006 | WO2006062933A3 Stable compositions of fenofibrate with fatty acid esters |
| 08/31/2006 | WO2006059194A3 Pharmaceutical sustained-release composition containing clozapine |
| 08/31/2006 | WO2006059029A3 Solutions viscoelastiques renfermant du hyaluronate de sodium et de l ' hydroxypropylmethylcellulose |
| 08/31/2006 | WO2006056711A3 Oral medicament for the modified release of at least one active principle, in multimicrocapsule form |
| 08/31/2006 | WO2006053712A3 Process and device for producing finely divided liquid-liquid formulations, and the uses of these liquid-liquid formulations |
| 08/31/2006 | WO2006053564A3 Stabilisation of granules comprising active compounds |
| 08/31/2006 | WO2006044377A3 Purified phospholipid-non-steroidal anti-inflammatory drug associated compositions and methods for preparing and using same |
| 08/31/2006 | WO2006035418A3 Microcapsules comprising a methylxanthine and a corticosteroid |
| 08/31/2006 | WO2006035417A3 Dihydropyrimidine microcapsule - formulations |
| 08/31/2006 | WO2006027786A8 Use of liposomal glucocorticoids for treating inflammatory states |
| 08/31/2006 | WO2006024284A3 Atrium patch |
| 08/31/2006 | WO2006020522A3 Multiplex drug delivery device |
| 08/31/2006 | WO2006017852A3 Pharmaceutical compositions for controlled release delivery of biologically active compounds |
| 08/31/2006 | WO2006000228A3 Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention |
| 08/31/2006 | WO2005115380A3 Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins |
| 08/31/2006 | WO2005067890A3 Controlled release cgrp delivery composition for cardiovascular and renal indications |
| 08/31/2006 | WO2005065717A3 Liquid formulations of antibody conjugates |
| 08/31/2006 | WO2005044273A8 Controlled release delivery system for nasal applications |
| 08/31/2006 | WO2005038430A3 Viral fibers |
| 08/31/2006 | WO2005030142A3 Rifalazil formulations |
| 08/31/2006 | WO2005013712A3 Chewing gum and confectionary compositions containing a stain-removing complex |
| 08/31/2006 | WO2005009289A9 Apparatus and methods for control of intravenous fluids |
| 08/31/2006 | WO2004093937A3 Dialysis valve and method |
| 08/31/2006 | US20060195067 Delivery of immune response modifier compounds |
| 08/31/2006 | US20060194826 Pharmaceutical combinations of hydrocodone and naltrexone |
| 08/31/2006 | US20060194822 Treatment for renal fibrosis |
| 08/31/2006 | US20060194775 Estradiol metabolites for the treatment of pulmonary hypertension |
| 08/31/2006 | US20060194771 metals or emissive substances introduced into azobenzene to obtain emissive azobenzene derivatives; aggregate particles; |
| 08/31/2006 | US20060194757 urinary tract incfections; for instillation to bladder |
| 08/31/2006 | US20060194744 Illudin analogs useful as antitumor agents |
| 08/31/2006 | US20060194729 Method of promoting natural bypass |
| 08/31/2006 | US20060194727 Prevention and reduction of blood loss |
| 08/31/2006 | US20060194722 orally administering to human a composition comprising salmon calcitonin in free or salt form and a delivery agent selected from N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAG), and disodium salts |
| 08/31/2006 | US20060194721 Tissue regeneration |
| 08/31/2006 | US20060194717 reduced tissue accumulation of the glycopeptide antibiotic, reduced nephrotoxicity and reduced histamine release; side effect reduction |
| 08/31/2006 | US20060194716 Polyacid glycopeptide derivatives |
| 08/31/2006 | US20060194030 Methods for identification and verification |
| 08/31/2006 | US20060193921 Hydrophilic beads for use in topical formulations |
| 08/31/2006 | US20060193919 Comprises a metal-containing anti-cancer drug being adsorbed onto or included in oxidized porous carbon nanohorns; novel drug carrier, which is excellent in characteristics of drug adsorption or inclusion and releasing properties |
| 08/31/2006 | US20060193918 Solvent/polymer solutions as suspension vehicles |
| 08/31/2006 | US20060193917 potentiating radiotherapy of lung cancer treatment by administering 4(5)-nitro-L-histidine to increase anticarcinogenic agent synergistic effect |
| 08/31/2006 | US20060193916 Formulations of peptides for periodontal and dental treatments |
| 08/31/2006 | US20060193915 Compression coated tablets |
| 08/31/2006 | US20060193914 Crush resistant delayed-release dosage forms |
| 08/31/2006 | US20060193913 And salts such as the maleate in particulate form, prepared by wet milling; controlled release compositions |
| 08/31/2006 | US20060193912 Controlled release O-desmethylvenlafaxine formulations |
| 08/31/2006 | US20060193911 Controlled release venlafaxine formulations |
| 08/31/2006 | US20060193910 Tablets with improved drug substance dispersibility |
| 08/31/2006 | US20060193909 Breath freshening pressed tablets and methods of making and using same |
| 08/31/2006 | US20060193908 Extended release formulations of poorly soluble antibiotics |
| 08/31/2006 | US20060193907 NGNA compositions and methods of use |
| 08/31/2006 | US20060193906 Sugar-modified liposome and products comprising the liposome |
| 08/31/2006 | US20060193905 Direct cellular energy delivery system |
| 08/31/2006 | US20060193904 Encapsulation of drugs in liposomes; encapsulated transition metal ions and encapsulated drugs, where if the drug is soley doxorubicin, the metal ion is not solely manganese, and the liposomes do not comprise an ionophore |
| 08/31/2006 | US20060193903 hydrophobic drug having (a) glycoside like GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal- as sugar moiety (b) phosphatidylcholines (c) stearylamine/oleylamine; composition improves the low solubility of gylcoside; cholestenol/ ceramide/naphthalene-2-methanol -glycoside anticancer drug; improved drug delivery |
| 08/31/2006 | US20060193902 Pharmaceutical compositions containing active agents having a lactone group and transition metal ions |
| 08/31/2006 | US20060193901 Particularly drugs and cosmetic agents; an ethoxylated oil, fatty acid, fatty alcohol, or fatty amine having between 10 and 19 ethoxy units, and the delivered agent, especially analgesics, antiinflammatory agents or antiwrinkle agents; improved penetration and bioavailability |
| 08/31/2006 | US20060193899 Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
| 08/31/2006 | US20060193898 Line up of wipes products incorporating targeted sensory elements |
| 08/31/2006 | US20060193896 Process for manufacturing a delivery system for active components as part of an edible composition |
| 08/31/2006 | US20060193878 Method of Preparing Gas Delivering Perfluorocarbon Emulsions With Non-Fluorinated Surfactants |
| 08/31/2006 | US20060193877 Compositions and methods of making sustained release liquid formulations |
| 08/31/2006 | US20060193873 Functionallly reconstituted viral membranes containing adjuvant |
| 08/31/2006 | US20060193871 transmission and, or amplification of signal; oral or enteric administering, dissolving, absorption; peptide yy; obesity therapy |
| 08/31/2006 | US20060193842 Formulations to increase in vivo survival of probiotic bacteria and extend their shelf-life |
| 08/31/2006 | US20060193823 Hydrolytically degradable carbamate derivatives of poly (Ethylene Glycol) |
| 08/31/2006 | US20060193822 Antiseptic spermicidal composition and means for its application |
| 08/31/2006 | US20060193799 Method of Making Perfluorocarbon Emulsions With Non-Fluorinated Surfactants |
| 08/31/2006 | US20060193798 Aqueous Polymer Dispersion |
| 08/31/2006 | US20060193790 Promoting whole body health |
| 08/31/2006 | US20060193789 Surfacant, film forming agent, water, gas propellant; plant and animal extracts and oils; may include malathion |
| 08/31/2006 | US20060193788 Acute treatment of headache with phenothiazine antipsychotics |
| 08/31/2006 | US20060193787 Nanoparticle-based drug delivery system |
| 08/31/2006 | US20060193786 Pharmaceutical composition for intranasal administration containing a CGRP antagonist |
| 08/31/2006 | US20060193783 Low dose corticosteroid composition |
| 08/31/2006 | US20060193782 Abuse-proofed dosage form |
| 08/31/2006 | US20060193769 Drug releasing biodegradable fiber for delivery of therapeutics |
| 08/31/2006 | US20060191850 Method and a device for preparing a medical liquid |
| 08/31/2006 | US20060191375 Methods for fine powder formation |
| 08/31/2006 | US20060191374 Cross-linked polymeric nanoparticles and metal nanoparticles derived therefrom |
| 08/31/2006 | US20060191373 Cross-linked polymeric nanoparticles and metal nanoparticles derived therefrom |
| 08/31/2006 | US20060191239 Process and machine for automated manufacture of gastro-retentive capsules |
| 08/31/2006 | CA2821046A1 An hiv protease inhibitor solid dosage formulation for the treatment of hiv/aids under fasting conditions |
| 08/31/2006 | CA2805761A1 Nanoparticles of gemcitabine derivatives |
| 08/31/2006 | CA2768075A1 Dosage form containing oxycodone and naloxone |
| 08/31/2006 | CA2600011A1 Rasagiline formulations of improved content uniformity |
| 08/31/2006 | CA2599213A1 Dronabinol compositions and methods of using same |
| 08/31/2006 | CA2599121A1 Method for production of a preparation of a solid dmso-containing silicone oil emulsion for the binding of reactive oxygen compounds in human and animal bodies |
| 08/31/2006 | CA2598953A1 Nasal delivery device for delivering substance to a nasal cavity of a subject |
| 08/31/2006 | CA2598827A1 An hiv protease inhibitor solid dosage formulation for the treatment of hiv/aids under fasting conditions |
| 08/31/2006 | CA2598762A1 Tablets with improved drug substance dispersibility |
| 08/31/2006 | CA2598759A1 Trofosfamide containing film-coated tablets and procedure for its production |
| 08/31/2006 | CA2598653A1 Spreadable warming lubricant |
| 08/31/2006 | CA2598588A1 Thickened spreadable warming lubricant |
| 08/31/2006 | CA2598441A1 Nanoparticulate formulations of docetaxel and analogues thereof |